Evaluation of the applicability of the aquatic ascomycete Phoma sp. UHH 5-1-03 for the removal of pharmaceutically active compounds from municipal wastewaters using membrane bioreactors.

Abstract

Membrane bioreactors (MBRs) augmented with terrestrial white-rot basidiomycetes have already been tested for the removal of pharmaceutically active compounds (PhACs) from wastewaters. Within the present study, an aquatic ascomycete (Phoma sp.) was initially demonstrated to efficiently remove several PhACs at their real environmental trace concentrations from nonsterile municipal wastewater on a laboratory scale. Then, a pilot MBR was bioaugmented with Phoma sp. and successively operated in two configurations (first treating full-scale MBR effluent as a posttreatment, and then treating raw municipal wastewater). Treatment of influent wastewater by the Phoma-bioaugmented pilot MBR was more efficient than influent treatment by a concomitantly operated full-scale MBR lacking Phoma sp and posttreatment of full-scale MBR permeate using the pilot MBR. A stable removal of the PhACs carbamazepine (CBZ) and diclofenac (DF) (39 and 34% on average, respectively) could be achieved throughout the pilot MBR influent treatment period of 51 days, without the need for additional nutrient supplementation (full-scale MBR: on average, 15% DF but no CBZ removed during 108 days). The long-term presence of Phoma sp. in the pilot MBR could be demonstrated using fluorescence in situ hybridization analysis, but still open questions regarding its long-term activity maintenance remain to be answered.